Decoy Therapeutics (FP11) Ratios
Decoy Therapeutics Ratios
DE:FP11's free cash flow for Q2 2026 was $-2.69M. For the 2026 fiscal year, DE:FP11's free cash flow was decreased by $-42.42K and operating cash flow was $-2.65M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.13 | 1.98 | 5.02 | 3.40 | 14.29 |
| Quick Ratio | 2.13 | 1.98 | 5.02 | 3.40 | 14.29 |
| Cash Ratio | 2.07 | 1.61 | 4.54 | 2.84 | 13.84 |
| Solvency Ratio | -2.42 | -3.69 | -9.65 | -7.41 | -6.04 |
| Operating Cash Flow Ratio | -0.93 | -2.99 | -9.89 | -4.12 | -4.83 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -20.40 | -44.35 | 0.00 | 0.00 |
| Net Current Asset Value | $ 5.82M | $ 1.48M | $ 5.22M | $ 10.25M | $ 28.05M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.07 | 0.04 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.15 | 0.05 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.13 | 0.05 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.88 | 2.00 | 1.25 | 1.41 | 1.05 |
| Debt Service Coverage Ratio | 0.00 | -25.11 | -44.49 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.01 | 0.02 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 3.46 | 1.32 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.86 | 0.40 | 0.44 | 0.53 | 2.28 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 99.24% | 97.24% | 97.27% | 99.27% | 99.65% |
| Return on Assets (ROA) | -113.22% | -184.45% | -190.43% | -215.74% | -31.27% |
| Return on Equity (ROE) | -212.58% | -368.84% | -237.22% | -304.37% | -32.97% |
| Return on Capital Employed (ROCE) | -214.20% | -379.33% | -243.89% | -306.62% | -33.09% |
| Return on Invested Capital (ROIC) | -214.20% | -330.78% | -231.22% | -306.62% | -33.09% |
| Return on Tangible Assets | -113.22% | -184.45% | -190.43% | -215.74% | -39.94% |
| Earnings Yield | -333.69% | -26.24% | -73.52% | -120.95% | -62.22% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 9.06 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -40.30 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 40.30 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -10.02 | -70.55 | -58.73 | -123.61 | -739.04 |
| Free Cash Flow Per Share | -10.02 | -70.55 | -58.73 | -134.15 | -739.04 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -4282045.67 | -11.73 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -4282045.67 | -11.73 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | -20.40 | -44.35 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -128.67% | -21.30% | -75.30% | -73.07% | -49.71% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.30 | -3.81 | -1.36 | -0.83 | -1.61 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.64 | 14.05 | 3.23 | 2.52 | 0.53 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.78 | -4.69 | -1.33 | -1.37 | -2.01 |
| Price-to-Operating Cash Flow Ratio | -0.78 | -4.69 | -1.33 | -1.49 | -2.01 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.05 | 0.01 | 0.01 | 0.04 |
| Enterprise Value Multiple | 0.56 | -3.42 | -0.89 | -0.61 | 0.68 |
| Enterprise Value | -6.96M | 19.03M | 11.45M | 14.03M | -8.69M |
| EV to EBITDA | 0.56 | -3.42 | -0.89 | -0.61 | 0.68 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 1.44 | -4.21 | -0.89 | -0.73 | 0.85 |
| EV to Operating Cash Flow | 1.44 | -4.21 | -0.89 | -0.80 | 0.85 |
| Tangible Book Value Per Share | 12.23 | 23.57 | 24.17 | 72.96 | 2163.24 |
| Shareholders’ Equity Per Share | 12.23 | 23.57 | 24.17 | 72.96 | 2805.61 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -25.99 | -86.92 | -57.34 | -222.06 | -925.10 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.97 | 1.38 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.39 | 0.81 | 1.02 | 0.56 | 0.80 |
Currency in USD
